Lilly(Eli) & Co

**Strong Revenue Growth**: Eli Lilly reported a 42% growth in Q3 revenue, driven primarily by its key products Mounjaro and Zepbound, with new product revenue increasing by over $3 billion. Excluding the divested olanzapine portfolio, the growth rate was around 17%.

**Guidance Update**: For Q4 2024, Lilly expects revenue in the range of $45.4 billion to $46 billion, indicating a potential growth acceleration of approximately 50% compared to Q4 2023. This optimistic outlook is driven by increased production capacity and anticipated demand generation activities.

**Pipeline Developments**: Key milestones included the approval of Ebglyss for atopic dermatitis and Kisunla for Alzheimer's disease. Additionally, promising Phase 3 data for tirzepatide in obesity and donanemab for Alzheimer's contributes positively to the pipeline outlook.